FDA panel unanimously backs Regeneron eye drug

Jun 17, 2011 By MATTHEW PERRONE , AP Health Writer

(AP) -- A panel of federal health experts voted unanimously in favor of a new eye drug from Regeneron, bringing the company one step closer to competing against a blockbuster Roche drug that currently dominates the market.

A advisory panel voted 10-0 Friday that Regeneron's drug is a safe and effective treatment for a condition that can lead to blindness in seniors, according to an agency spokeswoman. More than 200,000 new cases of the condition, called wet macular degeneration, are diagnosed each year.

The FDA is not required to follow the group's advice, though it often does.

If approved, Regeneron's will be the first product to compete with Roche's Lucentis, which posts sales of $1.5 billion annually. The FDA is scheduled to make its final decision on approval by Aug. 20. If approved, Regeneron and its partner Bayer Pharmaceuticals will co-market the drug under the brand name Eylea.

Analysts have high expectations for Regeneron's drug because it requires fewer injections than Lucentis: once every two months, versus once a month. Company executives say the extended dosing regimen should appeal to both doctors and patients.

Shares of Tarrytown, N.Y.-based Regeneron Pharmaceuticals Inc. were halted from trading pending the panel vote.

Wet, is the most common cause of blindness among older Americans. The condition causes new blood vessels to grow in the eye and leak blood and fluid, damaging the retina and distorting vision.

The "dry" form of the condition is the most common type of macular degeneration, with the "wet" form considered the more advanced version of the disease.

Regeneron may face its toughest competition from another Roche drug called Avastin, which is chemically similar to Lucentis. Avastin is a cancer drug that doctors have used for many years to treat the eye disease even though it is not approved for that purpose. Specially-formulated injections of cost just $50, compared with $2,000 for .

Regeneron executives have not yet discussed how they will price their drug.

Explore further: Xtoro approved for swimmer's ear

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA says breast cancer drug did not extend lives

Jul 16, 2010

(AP) -- Federal health scientists said Friday that follow-up studies of a Roche breast cancer drug show it failed to slow tumor growth or extend patient lives, opening the door for a potential withdrawal in that indication.

Experts veto Avastin as a breast cancer treatment

Jul 20, 2010

(AP) -- A panel of cancer experts said Tuesday that the government should remove its endorsement of Roche's drug Avastin for breast cancer, after follow-up studies failed to show benefits for patients.

Recommended for you

Xtoro approved for swimmer's ear

9 hours ago

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

10 hours ago

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.